Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Extracorporeal shock wave therapy improves erectile function in patients with Peyronie’s disease. However, erectile dysfunction still persists in many cases. We aimed to investigate the effects of extracorporeal shock wave therapy plus tadalafil 5 mg once daily in the management of patients with Peyronie’s disease and erectile dysfunction not previously treated. One hundred patients were enrolled in a prospective, randomized, controlled study. Patients were randomly allocated to receive either extracorporeal shock wave therapy alone for 4 weeks (n = 50) or extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks (n = 50). Main outcome measures were: erectile function (evaluated through the shortened version of the International Index of Erectile Function), pain during erection (evaluated through a Visual Analog Scale), plaque size, penile curvature and quality of life (evaluated through an internal questionnaire). Follow‐up evaluations were performed after 12 and 24 weeks. In both groups, at 12 weeks follow‐up, mean Visual Analog Scale score, mean International Index of Erectile Function score and mean quality of life score ameliorated significantly while mean plaque size and mean curvature degree were unchanged. Intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and quality of life score in patients receiving the combination. After 24 weeks, intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and mean quality of life score in patients that received extracorporeal shock wave therapy plus tadalafil. In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie’s disease and erectile dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, R., Catania, J., Lue, T., Althof, S., Henne, J., Hellstrom, W., & Levine, L. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00883.x · Cited by 197
Weidner, W., Schroeder-Printzen, I., Weiske, W.-H., & Vosshenrich, R. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65370-9 · Cited by 121
Research works printed but not linked: 23
- 10.1007/s11934-000-0010-8 · DOI
- 10.1590/S1677-55382004000300004 · DOI
- 10.1016/j.eururo.2006.02.048 · doi:10.1016/j.eururo.2006.02.048
- 10.1185/03007990802498440 · DOI
- 10.1111/j.1464-410X.2006.05955.x · DOI · Paper page
- 10.1111/j.1743-6109.2008.01104.x · DOI · Paper page
- 10.1038/nrurol.2010.24 · DOI
- 10.1097/01.ju.0000099891.68488.4e · DOI
- 10.1097/01.ju.0000108060.30363.8d · DOI · Paper page
- 10.1046/j.1464-410x.2001.02241.x · DOI · Paper page
- 10.1038/sj.ijir.3901247 · DOI
- 10.1016/S0090-4295(02)01527-3 · DOI
- 10.1038/sj.ijir.3900912 · DOI
- 10.1111/j.1743-6109.2005.20360.x · DOI · Paper page
- 10.1016/S0302-2838(02)00225-7 · DOI
- 10.1111/j.1743-6109.2005.20113.x · DOI · Paper page
- 10.1016/S0022-5347(06)00270-9 · DOI · Paper page
- 10.1016/j.eururo.2009.05.012 · DOI · Paper page
- 10.1007/s00120-009-2089-y · DOI
- Pryor JP., 1988, Peyronie’s disease and impotence, Acta Urol Belg, 56, 317
- 10.1038/sj.ijir.3900472 · DOI · Paper page
- 10.1016/j.niox.2003.12.002 · DOI · Paper page
- 10.1017/S0266462300161173 · doi:10.1017/s0266462300161173
Cited by
Peyronie’s Disease: AUA Guideline
Nehra, A., Alterowitz, R., Culkin, D. J., Faraday, M. M., Hakim, L. S., Heidelbaugh, J. J., Khera, M., Kirkby, E., McVary, K. T., Miner, M. M., et al. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.05.098 · Cited by 416
Evidence-Based Management Guidelines on Peyronie's Disease
Chung, E., Ralph, D., Kagioglu, A., Garaffa, G., Shamsodini, A., Bivalacqua, T., Glina, S., Hakim, L., Sadeghi-Nejad, H., & Broderick, G. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.062 · Cited by 227
Bella, A. J., Lee, J. C., Grober, E. D., Carrier, S., Benard, F., & Brock, G. B. (2018) · Canadian Urological Association Journal · doi:10.5489/cuaj.5255 · Cited by 68
Nonsurgical management of Peyronie’s disease
Tsambarlis, P., & Levine, L. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-018-0117-7 · Cited by 64
Peyronie’s disease: pharmacological treatments and limitations
Li, E. V., Esterquest, R., Pham, M. N., Panken, E. J., Amarasekera, C., Siebert, A., Bajic, P., & Levine, L. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1903873 · Cited by 24
Metadata
- Authors
- Palmieri, A., Imbimbo, C., Creta, M., Verze, P., Fusco, F., & Mirone, V.
- Venue
- International Journal of Andrology
- Publisher
- Wiley
- Published
- 2011-11-15
- Volume
- 35
- Issue
- 2
- Pages
- 190-195
- ISSN
- 0105-6263 (ISSN-L)
- 1365-2605
- OpenAlex
- W1541254912
- Cited by
- 109
- References
- 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. https://app.cochat.ai/papers/10.1111/j.1365-2605.2011.01226.x
- The paper
- Palmieri, A., Imbimbo, C., Creta, M., Verze, P., Fusco, F., & Mirone, V. (2012). Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. International Journal of Andrology. https://doi.org/10.1111/j.1365-2605.2011.01226.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.